CIK 0000906709 · Non-accelerated filer<br>Smaller reporting company
NEKTAR THERAPEUTICS
Sign in to watch- Ticker
- NKTR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 943134940
- Phone
- 4154825300
- Business address
- 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
- Former names
- INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $43,476
- in 2 filings
Net −$43,476. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-12-16 | Wilson Mark Andrew SVP & General Counsel | Grant or award · Stock Option | +67,150 | 67,150 | ||
| 2021-12-16 | Thomsen Jillian B. SVP & Chief Accounting Officer | Grant or award | +21,200 | 167,681 | ||
| 2021-12-16 | Thomsen Jillian B. SVP & Chief Accounting Officer | Grant or award · Stock Option | +37,600 | 37,600 | ||
| 2021-12-16 | ROBIN HOWARD W President & CEO | Grant or award | +126,050 | 601,500 | ||
| 2021-12-16 | ROBIN HOWARD W President & CEO | Grant or award · Stock Option | +223,750 | 223,750 | ||
| 2021-12-16 | NORTHCOTT JOHN SVP & Chief Commercial Officer | Grant or award | +37,800 | 232,654 | ||
| 2021-12-16 | NORTHCOTT JOHN SVP & Chief Commercial Officer | Grant or award · Stock Option | +67,150 | 67,150 | ||
| 2021-12-16 | Labrucherie Gil M SVP, COO & CFO | Grant or award | +52,950 | 309,182 | ||
| 2021-12-16 | Labrucherie Gil M SVP, COO & CFO | Grant or award · Stock Option | +94,000 | 94,000 | ||
| 2021-11-18 | Labrucherie Gil M SVP, COO & CFO | Sale | −3,000 | $12.69 | $38K | 256,682 |
| 2021-11-16 | Labrucherie Gil M SVP, COO & CFO | Sale | −21,149 | $13.16 | $278K | 259,682 |
| 2021-11-16 | Zalevsky Jonathan Chief R&D Officer | Sale | −20,869 | $13.16 | $275K | 232,084 |
| 2021-11-16 | Wilson Mark Andrew SVP & General Counsel | Sale | −6,564 | $13.16 | $86K | 86,436 |
| 2021-11-16 | Thomsen Jillian B. SVP & Chief Accounting Officer | Sale | −6,741 | $13.16 | $89K | 145,981 |
| 2021-11-16 | ROBIN HOWARD W President & CEO | Sale | −42,773 | $13.16 | $563K | 475,450 |
| 2021-11-16 | NORTHCOTT JOHN SVP & Chief Commercial Officer | Sale | −6,061 | $13.16 | $80K | 194,854 |
| 2021-11-15 | Zalevsky Jonathan Chief R&D Officer | Grant or award | +40,150 | 252,953 | ||
| 2021-11-15 | Wilson Mark Andrew SVP & General Counsel | Grant or award | +20,100 | 93,000 | ||
| 2021-11-15 | Thomsen Jillian B. SVP & Chief Accounting Officer | Grant or award | +14,900 | 152,722 | ||
| 2021-11-15 | ROBIN HOWARD W President & CEO | Grant or award | +94,100 | 518,223 |
Page 10 of 18 · 355 trades